Pliant Therapeut Rg

Biopharma innovator targeting fibrosis with oral integrin inhibitors: lead dual‑selective PK‑74809 in Phase II for pulmonary fibrosis and PSC, plus liver fibrosis and oncology candidates.

Headquarters: United States (USA)

Pliant Therapeut Rg Logo
Company Profile
  • Employees: 171
  • HQ: South San Francisco
Traded Instruments
+ Add Instrument 1
Symbol Name Type Exchange Currency ISIN Status Actions
PLRX Pliant Therapeut Rg
Cap: 0.1B
EQUITY NMS USD US7291391057 Active
📈
Home Login